Chromatin immunoprecipitation (ChIP) Sequencing Market Forecast Reaching $25.37 Billion by 2029 at 13% CAGR
Discover trends, market shifts, and competitive outlooks for the chromatin immunoprecipitation (chip) sequencing industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Is the Estimated Market Size of the Chromatin immunoprecipitation (ChIP) Sequencing Market In 2029?
The market size for chromatin immunoprecipitation (ChIP) sequencing has seen significant expansion in the past years. It’s projected to increase from a value of $13.89 billion in 2024 to reach $15.6 billion in 2025, representing a compound annual growth rate (CAGR) of 12.3%. The historic growth of this market can be associated with the insights provided into gene regulation, a boost in epigenetics research, improved use of data analysis and bioinformatics tools, as well as cost decreases and enhanced scalability.
The market size for Chromatin Immunoprecipitation (ChIP) sequencing is predicted to experience significant expansion in the coming years, with expectations for a surge up to $25.37 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.9%. The anticipated market growth during the forecast period is linked to factors such as competitive industrial investment, clinical implementation and diagnostic usage, increasing demand for biomarker identification, swift progression of bioinformatics tools, and the escalating use in drug discovery. Key trends for the anticipated period consist of clinical conversions and diagnostic applications, emphasis on histone alterations, usage in emerging research fields, advances in sample processing, and integration of multi-omics.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13265&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chromatin immunoprecipitation (ChIP) Sequencing Market?
The escalating occurrence of prostate cancer is projected to stimulate the chromatin immunoprecipitation (ChIP) sequencing market’s expansion. This form of cancer evolves in the prostate gland, a small, walnut-shaped gland in males that aids in semen production. In the research of prostate cancer, ChIP-seq provides an extensive perspective of the molecular happenings motivating the ailment, yielding necessary insights that can pave the way for improved comprehension of its biological mechanisms and the creation of more precise and practical treatment options. For example, the American Cancer Society, a renowned American organization dedicated to cancer prevention, estimated in January 2023 that prostate cancer accounted for 288,300 new cases and 34,700 deaths within the US in 2023. Thus, the escalating occurrence of prostate cancer is fueling the growth of the chromatin immunoprecipitation (ChIP) sequencing market. Furthermore, the rising acceptance of personalized medicine is projected to accelerate the growth of the chromatin immunoprecipitation (ChIP) sequencing market. Personalized medicine signifies a modern approach to healthcare and medical treatment that tailors medical decisions, interventions, and treatments according to individual patient attributes. Personalized medicine often depends on identifying specific genetic or epigenetic markers linked to diseases or conditions. ChIP sequencing serves as a potent resource for mapping epigenetic adjustments, such as DNA methylation and histone modifications, which can be critical in understanding the genetic foundation of diseases. For instance, in 2022, the Personalized Medicine Coalition, a professional membership organization in the US, revealed that the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) had approved 37 novel molecular entities (NMEs). The Personalized Medicine Coalition (PMC) recognized 12 out of 35 therapeutic NMEs, roughly 34% of them, as customized medications. Thus, the rising acceptance of personalized medicine is fueling the growth of the chromatin immunoprecipitation (ChIP) sequencing market.
Which Key Market Segments Comprise the Chromatin immunoprecipitation (ChIP) Sequencing Market and Drive Its Revenue Growth?
The chromatin immunoprecipitation (ChIP) sequencing market covered in this report is segmented –
1) By Type: DNase-Sequencing, FAIRE-Sequencing
2) By Technology: Targeted Sequencing And Re-Sequencing, Whole Genome Sequencing And Whole Exome Sequencing
3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis
4) By Application: Consumables And Reagents, Service, Other Applications
5) By End-User: Academic Research Institutes, Clinical Research Institutes, Hospitals And Clinics, Pharmaceuticals And Biotechnology Companies, Other End Users
Subsegments:
1) By DNase-Sequencing: DNase I Hypersensitivity Mapping, DNase-Seq For Open Chromatin Regions
2) By FAIRE-Sequencing: Formaldehyde-Assisted Isolation Of Regulatory Elements (FAIRE), FAIRE-Seq For Active Regulatory Regions
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13265&type=smp
Which Areas Are Leading Regions in the Chromatin immunoprecipitation (ChIP) Sequencing Market Expansion Across the Globe?
North America was the largest region in the chromatin immunoprecipitation (ChIP) sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chromatin immunoprecipitation (chip) sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Key Market Trends in theChromatin immunoprecipitation (ChIP) Sequencing Market Over the Coming Years?
Leading firms in the chromatin immunoprecipitation (ChIP) sequencing market are emphasizing on the development of new technologies such as hmqChIP-seq (high-throughput multiplex quantitative Chromatin Immunoprecipitation sequencing) to boost the efficacy and precision of epigenomic studies. This innovative approach is paving the way for breakthroughs in drug development and personalized healthcare. hmqChIP-seq is an advanced tool formulated to advance the understanding of epigenetic alterations throughout the genome. As an example, Epigenica, a life science tech firm based in Sweden, introduced its EpiFinder Platform in June 2024. This platform is equipped with the patented hmqChIP-seq technology enabling high-throughput, multiplex quantitative analysis in epigenomic research. This inventive platform facilitates the generation of 192 genome-wide profiles concurrently from up to 24 samples, making it a game-changer for conducting large-scale experiments with unmatched speed and cost-effectiveness.
View the full report here:
How Is the Chromatin immunoprecipitation (ChIP) Sequencing Market Conceptually Defined?
Chromatin immunoprecipitation (ChIP) sequencing is a powerful molecular biology technique used to study the interactions between proteins and DNA within a cell. It provides insights into the binding patterns of specific proteins (often transcription factors or other chromatin-associated proteins) to the DNA in a genome-wide manner.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13265
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
